GE HealthCare reports third quarter 2026 financial results
• Delivers top- and bottom-line growth ahead of Company expectations and raises full-year 2026 guidance
• Organic orders growth of 4.0% , book-to-bill of 1.03 times and backlog of $23.7 billion
• Net income margin of 11.1% and Adjusted earnings before interest and taxes (EBIT) margin* of 16.6%; diluted EPS of $1.36 grew 39.1% and Adjusted EPS* of $1.34 grew 25.1%
• Cash flow from operating activities of $907 million and Free cash flow* of $793 million
GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2026.
GE HealthCare President and CEO Peter Arduini said, “We delivered strong top- line growth and margin expansion across all segments, and robust EPS growth in the third quarter. This reflects our teams’ commercial execution, disciplined operational focus enabled by Heartbeat, and continued customer adoption of our innovations. With our improved performance year-to-date and momentum in the business, we are raising guidance for the year.” Third quarter 2026 total company financial performance (1) • Revenues of $5.5 billion, up 7.2%, including Organic revenue growth* of 6.2%, with growth across all segments.
• Total orders up 4.0% organically, book-to-bill of 1.03 times and backlog of $23.7 billion, driven by healthy demand .
• Net income attributable to GE HealthCare of $615 million versus $446 million, and Adjusted EBIT* of $913 million versus $761 million.
• Net income margin of 11.1% versus 8.7%, up 250 basis points (bps). Adjusted EBIT margin* of 16.6% versus 14.8%, up 180 bps, with both measures driven by volume, price and cost productivity, and favorable year-over-year net tariff impact, partially offset by inflation.
Segment Advanced Imaging Pharmaceutical Patient Care ($ in millions) Solutions Diagnostics Solutions (AIS) (PDx) (PCS) Segment $3,873 $846 $793 Revenues YoY % change 6.1% 13.0% 8.5% YoY % Organic* 4.5% 13.8% 8.8% change Segment EBIT $593 $253 $68 YoY % change 15.8% 14.9% 148.8% Segment EBIT 15.3% 29.9% 8.6% Margin YoY change 130 bps 50 bps 480 bps
The Company announced that Jeannette Bankes, President and CEO, Patient Care Solutions, will be leaving for a CEO role at a publicly traded company. Neal Sandy, currently head of PCS Product Strategy and Management, brings more than 30 years of industry experience and will assume the role of President and CEO of PCS on November 16, 2026.
• Cash flow from operating activities of $907 million, up $314 million. Free cash flow* of $793 million, up $310 million. Both measures include a tariff refund of $55 million.
• Capital expenditures of $114 million compared to $110 million in the prior year.
• Cash and cash equivalents of $2.9 billion and access to $3.5 billion of revolving credit facilities. Total debt outstanding of $10.0 billion.
• Declared quarterly dividend of $0.04 per share to stockholders of record as of October 23, 2026, an increase of 14% from the previous quarter.
• In October 2026, the Company announced plans to acquire SOFIE Biosciences from Trilantic North America for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to customary closing conditions, including regulatory approvals.
• GE HealthCare expands general imaging ultrasound portfolio with LOGIQ Focus, elevating everyday ultrasound performance
• GE HealthCare to acquire SOFIE Biosciences, establishing a 'final mile' footprint for PET radiopharmaceutical supply in the U.S.
• GE HealthCare expands research collaboration to explore using generative AI for more personalized radiation therapy
• GE HealthCare announces CareIntellect for Operations, helping health systems optimize resources and expand access to care
• GE HealthCare aims to advance a new era in theranostics with StarGuide™ GX 4D SPECT/CT, now 510(k) pending with the U.S. FDA
• GE HealthCare’s Photonova™ Spectra gains CE Mark, expanding international access
• GE HealthCare unveils the next generation of the Vivid cardiovascular ultrasound portfolio, enabling advanced cardiac imaging across care settings
• GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue
The Company provides its outlook on a non-GAAP basis. Refer to the Non-GAAP financial measures in outlook section below for more details.
Certain columns and rows in this document may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.
Condensed Consolidated Statements of (In millions, Financial except share Position and per September 30, December 31, (Unaudited) share amounts) As of 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash, cash equivalents, $ 2,854 $ 4,512 and restricted cash Receivables – net of allowances of 3,925 3,955 $101 and $103 Inventories 2,628 2,234 Contract and other deferred 1,365 1,073 assets All other 723 726 current assets Current assets 11,495 12,501 Property, plant, and 3,219 3,092 equipment – net Goodwill 15,140 13,489 Other intangible 1,812 1,130 assets – net Deferred 4,423 4,491 income taxes All other non-current 2,283 2,205 assets Total assets $ 38,371 $ 36,906 Short-term $ 3 $ 508 borrowings Accounts 3,320 3,250 payable Contract 2,251 2,095 liabilities Current compensation 1,626 1,666 and benefits All other current 1,615 1,587 liabilities Current 8,815 9,105 liabilities Long-term 9,970 9,495 borrowings Non-current compensation 5,107 5,453 and benefits Deferred 318 193 income taxes All other non-current 2,297 2,061 liabilities Total 26,508 26,307 liabilities Commitments and contingencies Redeemable noncontrolling 234 209 interests Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 459,920,180 shares issued 5 5 as of September 30, 2026; 458,844,209 shares issued as of December 31, 2025 Treasury stock, at cost, 7,785,199 shares as of September 30, -525 -225 2026 and 3,107,626 shares as of December 31, 2025 Additional paid-in 6,797 6,707 capital Retained 6,795 5,281 earnings Accumulated other comprehensive -1,459 -1,388 income (loss) – net Total equity attributable 11,614 10,379 to GE HealthCare Noncontrolling 17 11 interests Total equity 11,630 10,390 Total liabilities, redeemable $ 38,371 $ 36,906 noncontrolling interests, and equity
Condensed Consolidated Statements of For the nine months Cash Flows ended (Unaudited) (In millions) September 30 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 1,608 $ 1,552 Adjustments to reconcile Net income to Cash from (used for) operating activities: Depreciation of property, plant, 235 213 and equipment Amortization of 241 219 intangible assets Gain on remeasurement of Nihon — -97 Medi-Physics equity method investment Net periodic postretirement -140 -208 benefit plan (income) expense Postretirement plan -243 -260 contributions Share-based 116 94 compensation Provision for 342 395 income taxes Cash paid during the year for income -301 -353 taxes Changes in operating assets and liabilities, excluding the effects of acquisitions:
Receivables 3 -6 Inventories -430 -217 Contract and other -265 -111 deferred assets Accounts payable 82 -119 Contract 130 1 liabilities Current compensation and -44 -29 benefits All other operating 33 -136 activities – net Cash from (used for) operating 1,365 937 activities Cash flows – investing activities Additions to property, plant and equipment and -392 -348 internal-use software Purchases of businesses, net of -2,293 -279 cash acquired Purchases of -52 -82 investments All other investing 10 -69 activities – net Cash from (used for) investing -2,726 -778 activities Cash flows – financing activities Net increase (decrease) in borrowings -1 — (maturities of 90 days or less) Newly issued debt, net of debt issuance 1,151 1,494 costs (maturities longer than 90 days) Repayments and other reductions -1,013 -265 (maturities longer than 90 days) Dividends paid to -48 -48 stockholders Repurchase of -300 -200 common stock Proceeds from stock issued under 12 25 employee benefit plans Taxes paid related to net share -36 -41 settlement of equity awards All other financing -20 -56 activities – net Cash from (used for) financing -255 910 activities Effect of foreign currency rate changes -42 68 on cash, cash equivalents, and restricted cash Increase (decrease) in cash, cash -1,658 1,137 equivalents, and restricted cash Cash, cash equivalents, and restricted 4,515 2,893 cash at beginning of year Cash, cash equivalents, and restricted $ 2,857 $ 4,030 cash at end of period Supplemental disclosure of cash flows information Cash paid during the year for $ -364 $ -327 interest Non-cash investing activities Acquired but unpaid property, plant, $ 124 $ 111 and equipment
The non-GAAP financial measures presented in this press release are supplemental measures of GE HealthCare’s performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows, and operating results, and assess its future prospects. When read in conjunction with the Company’s U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in GE HealthCare’s underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Descriptions of the reported non-GAAP measures are included below.
The Company reports Organic revenue and Organic revenue growth rate to provide management and investors with additional understanding and visibility into the underlying revenue trends of the Company’s established, ongoing operations, as well as provide insights into overall demand for its products and services. To calculate these measures, the Company excludes the effect of acquisitions, dispositions, and foreign currency rate fluctuations.
The Company reports EBIT, Adjusted EBIT, Adjusted EBIT margin, Adjusted net income, and Adjusted earnings per share to provide management and investors with an additional understanding of its business by highlighting the results from ongoing operations and the underlying profitability factors, on a normalized basis. To calculate these measures the Company excludes, and reflects in the detailed reconciliations below, the following adjustments as applicable: Interest and other financial charges – net, Net (income) loss attributable to noncontrolling interests, Non-operating benefit (income) costs, Benefit (provision) for income taxes and certain tax related adjustments, and certain non-recurring and/or non-cash items. GE HealthCare may from time to time consider excluding other non-recurring items to enhance comparability between periods. Adjusted EBIT margin is calculated by taking Adjusted EBIT divided by Total revenues for the same period.
The Company reports Adjusted tax expense and Adjusted ETR to provide management and investors with a better understanding of the normalized tax rate applicable to the business and provide more consistent comparability across periods. Adjusted tax expense excludes the income tax related to the pre-tax income adjustments included as part of Adjusted net income and certain income tax adjustments, such as adjustments to deferred tax assets or liabilities. The Company may from time to time consider excluding other non-recurring tax items to enhance comparability between periods. Adjusted ETR is Adjusted tax expense divided by income before income taxes less the pre-tax income adjustments referenced above.
The Company reports Free cash flow and Free cash flow conversion to provide management and investors with an important measure of the ability to generate cash on a normalized basis and provide insight into the Company’s flexibility to allocate capital. Free cash flow is Cash from (used for) operating activities – continuing operations including cash flows related to the additions and dispositions of property, plant, and equipment (“PP&E”) and additions of internal-use software. Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the capital required for debt repayments. Free cash flow conversion is calculated by taking Free cash flow divided by Adjusted net income.
Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes. In order to compensate for the discussed limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. The detailed reconciliations of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure are provided below, and no single financial measure should be relied on to evaluate our business.
Represents revenues attributable to acquisitions from the date the (1) Company completed the transaction through the end of four quarters following the transaction, excluding the impact of Foreign currency exchange already captured in lines elsewhere. (2) Represents revenues attributable to dispositions for the four quarters preceding the disposition date.
(1) Consists of severance, facility closures, and other charges associated with restructuring programs. Consists of legal, consulting, and other transaction and integration (2) fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. Costs and other adjustments related to the Spin-Off and separation (3) from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. (4) Consists of gains and losses resulting from the sale of assets and investments. Primarily relates to valuation adjustments for equity investments and (5) for the nine months ended September 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction. (6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025.
(1) Consists of severance, facility closures, and other charges associated with restructuring programs. Consists of legal, consulting, and other transaction and integration (2) fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation (3) agreements with GE, and other one-time costs. For the nine months ended September 30, 2025, an adjustment is included to eliminate the associated impact on Net (income) loss attributable to noncontrolling interests for applicable costs that impact earnings attributable to noncontrolling interests. (4) Consists of gains and losses resulting from the sale of assets and investments. Primarily relates to valuation adjustments for equity investments and (5) for the nine months ended September 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction. Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025. The associated tax (6) effect is presented on the Tax effect of reconciling items line. The net of tax impact of tariff refunds is $7 million and $88 million for the three and nine months ended September 30, 2026, respectively. The tax effect of reconciling items is calculated using the statutory (7) tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction. Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE. Additionally, includes the impact of (8) a foreign tax audit settlement for the three and nine months ended September 30, 2026; impacts from tax law changes for the three and nine months ended September 30, 2025; and tax impacts of the NMP acquisition for the nine months ended September 30, 2025.
(1) Consists of severance, facility closures, and other charges associated with restructuring programs. Consists of legal, consulting, and other transaction and integration (2) fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation (3) agreements with GE, and other one-time costs. For the nine months ended September 30, 2025, an adjustment is included to eliminate the associated impact on Net (income) loss attributable to noncontrolling interests for applicable costs that impact earnings attributable to noncontrolling interests. (4) Consists of gains and losses resulting from the sale of assets and investments. Primarily relates to valuation adjustments for equity investments and (5) for the nine months ended September 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction. Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025. The associated tax (6) effect is presented on the Tax effect of reconciling items line. The net of tax impact of tariff refunds is $0.02 and $0.19 for the three and nine months ended September 30, 2026, respectively. The tax effect of reconciling items is calculated using the statutory (7) tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction. Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE. Additionally, includes the impact of (8) a foreign tax audit settlement for the three and nine months ended September 30, 2026; impacts from tax law changes for the three and nine months ended September 30, 2025; and tax impacts of the NMP acquisition for the nine months ended September 30, 2025.
The tax effect of reconciling items is calculated using the statutory (1) tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction. Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE. Additionally, includes the impact of (2) a foreign tax audit settlement for the three and nine months ended September 30, 2026; impacts from tax law changes for the three and nine months ended September 30, 2025; and tax impacts of the NMP acquisition for the nine months ended September 30, 2025.
GE HealthCare calculates forward-looking non-GAAP financial measures, including Organic revenue growth, Adjusted EBIT margin, Adjusted ETR, Adjusted EPS, and Free cash flow based on internal forecasts that omit certain amounts that would be included in U.S. GAAP financial measures. GE HealthCare does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective U.S. GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or dispositions, timing and magnitude of restructuring activities, and revaluation of strategic investments, amongst other items. The timing and amounts of these items are uncertain and could have a substantial impact on GE HealthCare’s results in accordance with U.S. GAAP.
Management uses the following metrics to provide a leading indicator of current business demand from customers for products and services. • Organic orders growth: Rate of change period-over-period of contractual commitments with customers to provide specified goods or services for an agreed upon price, and excluding the effects of: (1) recent acquisitions and dispositions with less than a full year of comparable orders; and (2) foreign currency exchange rate fluctuations in order to present orders on a constant currency basis.
• Book-to-bill: Total orders divided by Total revenues within a given financial period (e.g., quarter or FY).
GE HealthCare will discuss its results during its live earnings c all tod ay, October 28, 2026 at 8:30 am ET/7:30 am CT. The webcast and accompanying slide presentation containing financial information can be accessed by visiting the investor section of the website at https://investor.gehealthcare.com/news- events/events. An archived version of the webcast will be available on the website after the call.
This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the Company’s business and expected financial performance, financial condition, and results of operations, including revenue, revenue growth, profit, taxes, earnings per share, and cash flows, and the Company’s outlook; changes in the Company’s leadership and related impacts; and the Company’s strategy, innovation, and acquisitions and investments. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, operating in highly competitive markets; global geopolitical and economic instability, including as a result of changes in trade and tariff policy, and international conflicts and tensions, including between Ukraine and Russia, in the Middle East, and in other regions; public health crises, epidemics, and pandemics, and their effects on the Company’s business; changes in or elimination of government subsidies, and changes in third-party and government reimbursement processes, rates, and contractual relationships, including related to government shutdowns, and changes in the mix of public and private payers; demand for the Company’s products, services, or solutions and factors that affect that demand; developments in the market in China; the Company’s ability to control increases in healthcare costs and any subsequent effect on demand for the Company’s products, services, or solutions; the Company’s ability to successfully complete strategic transactions; the actions or inactions of third parties with whom the Company partners and the various collaboration, licensing, and other partnerships and alliances the Company has with third parties; the impacts related to the Company’s increasing focus on and investment in cloud, edge computing, artificial intelligence, and software offerings; management of the Company’s supply chain and the Company’s ability to cost-effectively secure the materials it needs to operate its business; disruptions in the Company’s operations; the impact of potential information technology, cybersecurity, or data security breaches; maintenance and protection of the Company’s intellectual property rights, as well as maintenance of successful research and development efforts with respect to commercially successful products and technologies; the Company’s ability to attract and/or retain key talent and qualified employees; increasing attention to sustainability matters; compliance with the various legal, regulatory, tax, privacy, and other laws to which the Company is subject, such as the Foreign Corrupt Practices Act and similar anti-corruption and anti- bribery laws globally, and related changes, claims, inquiries, investigations, or actions; the impact of potential product liability claims or potential litigation, arbitration, or similar proceedings; the Company’s level of indebtedness and the impact of complying with the covenants and other terms of the Company’s debt instruments on its business. Please also see Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward- looking statements except as required by applicable law or regulation.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.
Full text with the tables
Exhibit 99
GE HealthCare reports third quarter 2026 financial results
• Delivers top- and bottom-line growth ahead of Company expectations and raises
full-year 2026 guidance
• Revenue growth of 7.2%, and Organic revenue growth* of 6.2%
• Organic orders growth of 4.0% , book-to-bill of 1.03 times and backlog of
$23.7 billion
• Net income margin of 11.1% and Adjusted earnings before interest and taxes
(EBIT) margin* of 16.6%; diluted EPS of $1.36 grew 39.1% and Adjusted EPS* of
$1.34 grew 25.1%
• Cash flow from operating activities of $907 million and Free cash flow* of
$793 million
Chicago, IL – October 28, 2026 –
GE HealthCare (Nasdaq: GEHC) today reported financial results for the third
quarter ended September 30, 2026.
GE HealthCare President and CEO Peter Arduini said, “We delivered strong top-
line growth and margin expansion across all segments, and robust EPS growth in
the third quarter. This reflects our teams’ commercial execution, disciplined
operational focus enabled by Heartbeat, and continued customer adoption of our
innovations. With our improved performance year-to-date and momentum in the
business, we are raising guidance for the year.”
Third quarter 2026 total company financial performance (1)
• Revenues of $5.5 billion, up 7.2%, including Organic revenue growth* of 6.2%,
with growth across all segments.
• Total orders up 4.0% organically, book-to-bill of 1.03 times and backlog of
$23.7 billion, driven by healthy demand .
• Net income attributable to GE HealthCare of $615 million versus $446 million,
and Adjusted EBIT* of $913 million versus $761 million.
• Net income margin of 11.1% versus 8.7%, up 250 basis points (bps). Adjusted
EBIT margin* of 16.6% versus 14.8%, up 180 bps, with both measures driven by
volume, price and cost productivity, and favorable year-over-year net tariff
impact, partially offset by inflation.
• Diluted EPS of $1.36 versus $0.98, up $0.38; Adjusted EPS* of $1.34 versus
$1.07, up $0.27 .
* Non-GAAP financial measure.
(1) All comparisons to prior-year period unless otherwise noted.
Third quarter 2026 segment financial performance
(Unaudited)
Segment Advanced Imaging Pharmaceutical Patient Care
($ in millions) Solutions Diagnostics Solutions
(AIS) (PDx) (PCS)
Segment $3,873 $846 $793
Revenues
YoY % change 6.1% 13.0% 8.5%
YoY % Organic* 4.5% 13.8% 8.8%
change
Segment EBIT $593 $253 $68
YoY % change 15.8% 14.9% 148.8%
Segment EBIT 15.3% 29.9% 8.6%
Margin
YoY change 130 bps 50 bps 480 bps
YoY refers to year-over-year comparison
The Company announced that Jeannette Bankes, President and CEO, Patient Care
Solutions, will be leaving for a CEO role at a publicly traded company. Neal
Sandy, currently head of PCS Product Strategy and Management, brings more than
30 years of industry experience and will assume the role of President and CEO of
PCS on November 16, 2026.
Third quarter capital deployment
(1)
• Cash flow from operating activities of $907 million, up $314 million. Free
cash flow* of $793 million, up $310 million. Both measures include a tariff
refund of $55 million.
• Capital expenditures of $114 million compared to $110 million in the prior
year.
• Cash and cash equivalents of $2.9 billion and access to $3.5 billion of
revolving credit facilities. Total debt outstanding of $10.0 billion.
• Declared quarterly dividend of $0.04 per share to stockholders of record as of
October 23, 2026, an increase of 14% from the previous quarter.
• In October 2026, the Company announced plans to acquire SOFIE Biosciences from
Trilantic North America for a purchase price of $945 million paid in cash. The
transaction is expected to close in the first half of 2027, subject to customary
closing conditions, including regulatory approvals.
Recent innovation and commercial highlights
• GE HealthCare expands general imaging ultrasound portfolio with LOGIQ Focus,
elevating everyday ultrasound performance
• GE HealthCare to acquire SOFIE Biosciences, establishing a 'final mile'
footprint for PET radiopharmaceutical supply in the U.S.
• GE HealthCare expands research collaboration to explore using generative AI
for more personalized radiation therapy
• GE HealthCare announces CareIntellect for Operations, helping health systems
optimize resources and expand access to care
• GE HealthCare aims to advance a new era in theranostics with StarGuide™ GX 4D
SPECT/CT, now 510(k) pending with the U.S. FDA
• GE HealthCare’s Photonova™ Spectra gains CE Mark, expanding international
access
• GE HealthCare unveils the next generation of the Vivid cardiovascular
ultrasound portfolio, enabling advanced cardiac imaging across care settings
• GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and
launch of ABUS StreamVue
* Non-GAAP financial measure.
(1) All comparisons to prior-year period unless otherwise noted.
2026 guidance
For the full-year 2026, the Company raises guidance as follows:
2025A Previous 2026E Updated 2026E
Organic Revenue Growth*(1) 3.5% 3.0% - 4.0% ~4.0%
Adjusted EBIT Margin* 15.3% 15.4% - 15.7% 15.5% - 15.7%
10 - 40 bps 20 - 40 bps
Adjusted ETR* 20.2% 20.0% - 21.0% Reaffirmed
Adjusted EPS* $4.59 $4.80 - $5.00 $4.95 - $5.05
4.6% - 9.0% 7.9% - 10.1%
Free Cash Flow* $1.5B ~$1.6B $1.6B+
The Company provides its outlook on a non-GAAP basis. Refer to the Non-GAAP
financial measures in outlook section below for more details.
Financial rounding
Certain columns and rows in this document may not sum due to the use of rounded
numbers. Percentages presented are calculated from the underlying whole-dollar
amounts.
* Non-GAAP financial measure.
(1) All comparisons to prior-year period unless otherwise noted.
Financial statements
Co…
Co…
St…
of
In…
(U… For For
(In the the
mi… thr… nine
ex… mon… mont…
per end… ended
sh… Sep… Sept…
am… 2026 30 2025 2026 30 2025
──────────────────────────────────────────────────────────────────────────────
Sa…
of $ 3,6… $ 3,3… $ 10,3… $ 9,7…
pr…
Sa…
of 1,9… 1,7… 5,575 5,1…
se…
To… 5,5… 5,1… 15,9… 14,…
re…
Co…
of 2,3… 2,2… 6,873 6,3…
pr…
Co…
of 916 884 2,685 2,5…
se…
Gr… 2,2… 1,9… 6,381 5,9…
pr…
Se…
ge… 1,1… 1,0… 3,334 3,1…
and
ad…
Re…
and 320 292 988 937
de…
To…
op… 1,4… 1,3… 4,322 4,0…
ex…
Op… 805 653 2,058 1,9…
in…
In…
and
ot…
fi… 122 111 332 335
ch…
–
net
No…
be… -50 -75 -146 -222
(i…
co…
Ot…
(i…
ex… -19 -26 -78 -124
–
net
In…
be… 752 643 1,950 1,9…
in…
ta…
Be…
(p…
for -129 -179 -342 -395
in…
ta…
Net 623 464 1,608 1,5…
in…
Net
(i…
lo…
at… -9 -18 -44 -57
to
no…
in…
Net
in…
at… $ 615 $ 446 $ 1,564 $ 1,4…
to
GE
He…
Ea…
per
sh…
at…
to
GE
He…
Ba… $ 1.36 $ 0.98 $ 3.45 $ 3.27
Di… 1.36 0.98 3.44 3.26
We…
nu…
of
sh…
ou…
Ba… 452 456 454 457
Di… 453 457 455 458
Condensed
Consolidated
Statements of (In millions,
Financial except share
Position and per September 30, December 31,
(Unaudited) share amounts) As of 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash, cash
equivalents, $ 2,854 $ 4,512
and restricted
cash
Receivables –
net of
allowances of 3,925 3,955
$101
and $103
Inventories 2,628 2,234
Contract and
other deferred 1,365 1,073
assets
All other 723 726
current assets
Current assets 11,495 12,501
Property,
plant, and 3,219 3,092
equipment –
net
Goodwill 15,140 13,489
Other
intangible 1,812 1,130
assets – net
Deferred 4,423 4,491
income taxes
All other
non-current 2,283 2,205
assets
Total assets $ 38,371 $ 36,906
Short-term $ 3 $ 508
borrowings
Accounts 3,320 3,250
payable
Contract 2,251 2,095
liabilities
Current
compensation 1,626 1,666
and benefits
All other
current 1,615 1,587
liabilities
Current 8,815 9,105
liabilities
Long-term 9,970 9,495
borrowings
Non-current
compensation 5,107 5,453
and benefits
Deferred 318 193
income taxes
All other
non-current 2,297 2,061
liabilities
Total 26,508 26,307
liabilities
Commitments
and
contingencies
Redeemable
noncontrolling 234 209
interests
Common stock,
par value
$0.01 per
share,
1,000,000,000
shares
authorized,
459,920,180
shares issued 5 5
as of
September 30,
2026;
458,844,209
shares
issued as of
December 31,
2025
Treasury
stock, at
cost,
7,785,199
shares as of
September 30, -525 -225
2026 and
3,107,626
shares as of
December 31,
2025
Additional
paid-in 6,797 6,707
capital
Retained 6,795 5,281
earnings
Accumulated
other
comprehensive -1,459 -1,388
income
(loss) – net
Total equity
attributable 11,614 10,379
to GE
HealthCare
Noncontrolling 17 11
interests
Total equity 11,630 10,390
Total
liabilities,
redeemable $ 38,371 $ 36,906
noncontrolling
interests, and
equity
Condensed
Consolidated
Statements of For the nine months
Cash Flows ended
(Unaudited) (In millions) September 30 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 1,608 $ 1,552
Adjustments to
reconcile Net
income to
Cash from (used
for) operating
activities:
Depreciation of
property, plant, 235 213
and
equipment
Amortization of 241 219
intangible assets
Gain on
remeasurement of
Nihon — -97
Medi-Physics equity
method investment
Net periodic
postretirement -140 -208
benefit plan
(income) expense
Postretirement plan -243 -260
contributions
Share-based 116 94
compensation
Provision for 342 395
income taxes
Cash paid during
the year for income -301 -353
taxes
Changes in
operating assets
and
liabilities,
excluding the
effects of
acquisitions:
Receivables 3 -6
Inventories -430 -217
Contract and other -265 -111
deferred assets
Accounts payable 82 -119
Contract 130 1
liabilities
Current
compensation and -44 -29
benefits
All other operating 33 -136
activities – net
Cash from (used
for) operating 1,365 937
activities
Cash flows –
investing
activities
Additions to
property, plant and
equipment and -392 -348
internal-use
software
Purchases of
businesses, net of -2,293 -279
cash
acquired
Purchases of -52 -82
investments
All other investing 10 -69
activities – net
Cash from (used
for) investing -2,726 -778
activities
Cash flows –
financing
activities
Net increase
(decrease) in
borrowings -1 —
(maturities of 90
days or less)
Newly issued debt,
net of debt
issuance 1,151 1,494
costs (maturities
longer than 90
days)
Repayments and
other reductions -1,013 -265
(maturities longer
than 90 days)
Dividends paid to -48 -48
stockholders
Repurchase of -300 -200
common stock
Proceeds from stock
issued under 12 25
employee benefit
plans
Taxes paid related
to net share -36 -41
settlement of
equity awards
All other financing -20 -56
activities – net
Cash from (used
for) financing -255 910
activities
Effect of foreign
currency rate
changes -42 68
on cash, cash
equivalents, and
restricted cash
Increase (decrease)
in cash, cash -1,658 1,137
equivalents, and
restricted cash
Cash, cash
equivalents, and
restricted 4,515 2,893
cash at beginning
of year
Cash, cash
equivalents, and
restricted $ 2,857 $ 4,030
cash at end of
period
Supplemental
disclosure of cash
flows
information
Cash paid during
the year for $ -364 $ -327
interest
Non-cash investing
activities
Acquired but unpaid
property, plant, $ 124 $ 111
and
equipment
Non-GAAP financial measures
The non-GAAP financial measures presented in this press release are supplemental
measures of GE HealthCare’s performance and its liquidity that the Company
believes will help investors understand its financial condition, cash flows, and
operating results, and assess its future prospects. When read in conjunction
with the Company’s U.S. GAAP results, these non-GAAP financial measures provide
a baseline for analyzing trends in GE HealthCare’s underlying businesses and can
be used by management as one basis for making financial, operational, and
planning decisions. Descriptions of the reported non-GAAP measures are included
below.
The Company reports Organic revenue and Organic revenue growth rate to provide
management and investors with additional understanding and visibility into the
underlying revenue trends of the Company’s established, ongoing operations, as
well as provide insights into overall demand for its products and services. To
calculate these measures, the Company excludes the effect of acquisitions,
dispositions, and foreign currency rate fluctuations.
The Company reports EBIT, Adjusted EBIT, Adjusted EBIT margin, Adjusted net
income, and Adjusted earnings per share to provide management and investors with
an additional understanding of its business by highlighting the results from
ongoing operations and the underlying profitability factors, on a normalized
basis. To calculate these measures the Company excludes, and reflects in the
detailed reconciliations below, the following adjustments as applicable:
Interest and other financial charges – net, Net (income) loss attributable to
noncontrolling interests, Non-operating benefit (income) costs, Benefit
(provision) for income taxes and certain tax related adjustments, and certain
non-recurring and/or non-cash items. GE HealthCare may from time to time
consider excluding other non-recurring items to enhance comparability between
periods. Adjusted EBIT margin is calculated by taking Adjusted EBIT divided by
Total revenues for the same period.
The Company reports Adjusted tax expense and Adjusted ETR to provide management
and investors with a better understanding of the normalized tax rate applicable
to the business and provide more consistent comparability across periods.
Adjusted tax expense excludes the income tax related to the pre-tax income
adjustments included as part of Adjusted net income and certain income tax
adjustments, such as adjustments to deferred tax assets or liabilities. The
Company may from time to time consider excluding other non-recurring tax items
to enhance comparability between periods. Adjusted ETR is Adjusted tax expense
divided by income before income taxes less the pre-tax income adjustments
referenced above.
The Company reports Free cash flow and Free cash flow conversion to provide
management and investors with an important measure of the ability to generate
cash on a normalized basis and provide insight into the Company’s flexibility to
allocate capital. Free cash flow is Cash from (used for) operating activities –
continuing operations including cash flows related to the additions and
dispositions of property, plant, and equipment (“PP&E”) and additions of
internal-use software. Free cash flow does not represent residual cash flows
available for discretionary expenditures, due to the fact that the measure does
not deduct the capital required for debt repayments. Free cash flow conversion
is calculated by taking Free cash flow divided by Adjusted net income.
Management recognizes that these non-GAAP financial measures have limitations,
including that they may be calculated differently by other companies or may be
used under different circumstances or for different purposes. In order to
compensate for the discussed limitations, management does not consider these
measures in isolation from or as alternatives to the comparable financial
measures determined in accordance with U.S. GAAP. The detailed reconciliations
of each non-GAAP financial measure to the most directly comparable U.S. GAAP
financial measure are provided below, and no single financial measure should be
relied on to evaluate our business.
Non-GAAP financial reconciliations
For For
the the
O… th… ni…
R… mo… mo…
U… en… en…
($ Se… Se…
in 30 % 30 %
m… 20… 20… ch… 20… 2… c…
──────────────────────────────────────────────────────────────────────────────
A… $ 3,… $ 3,… 6.… $ 11… $ 10… 7.…
r…
L… 68 — 140 —
A…
L… — — — —
D…
L…
F… -8 — 148 —
c…
e…
A…
O… $ 3,… $ 3,… 4.… $ 10… $ 10… 4.…
r…
P… $ 846 $ 749 13… $ 2,… $ 2,… 16…
r…
L… — — 50 1
A…
L… — — — —
D…
L…
F… -6 — 29 —
c…
e…
P…
O… $ 852 $ 749 13… $ 2,… $ 2,… 12…
r…
P… $ 793 $ 731 8.… $ 2,… $ 2,… (4…
r…
L… — — — —
A…
L… — — — —
D…
L…
F… -2 — 12 —
c…
e…
P…
O… $ 795 $ 731 8.… $ 2,… $ 2,… (4…
r…
O… $ 2 $ 15 (8… $ 26 $ 33 (2…
r…
L… — — — —
A…
L… — — — —
D…
L…
F… — — — —
c…
e…
O…
O… $ 2 $ 15 (8… $ 26 $ 33 (2…
r…
T… $ 5,… $ 5,… 7.… $ 15… $ 14… 6.…
r…
L… 68 — 190 1
A…
L… — — — —
D…
L…
F… -16 — 189 —
c…
e…
O… $ 5,… $ 5,… 6.… $ 15… $ 14… 4.…
r…
Represents revenues attributable to acquisitions from the date the
(1) Company completed the transaction through the end of four quarters
following the transaction, excluding the impact of Foreign currency
exchange already captured in lines elsewhere.
(2) Represents revenues attributable to dispositions for the four
quarters preceding the disposition date.
* Non-GAAP financial measure.
F… F…
t… t…
… t… n…
… m… m…
… e… e…
… S… % S… %
… U… 2… 30 2… c… 2… 30 2… c…
──────────────────────────────────────────────────────────────────────────────
…
…
… $ 6… $ 4… 3… % $ 1… $ 1… 4.6 %
…
…
…
…
…
…
… 1… 1… 3… 3…
…
…
–
…
…
…
… -… -… -… -…
…
…
…
…
… -… -… -… -…
…
…
…
…
…
…
… -9 -… -… -…
…
…
…
…
… 8… 6… 2… % 2… 2… 3.7 %
…
… 17 31 92 71
…
…
…
… 11 9 57 24
…
…
…
…
…
…
… 4 6 2 35
…
…
…
…
…
…
…
… -2 — -2 -5
…
…
…
…
…
…
… 61 41 1… 1…
…
…
…
…
…
… 6 -4 14 -…
…
…
…
… 9 — 1… —
…
… $ 9… $ 7… 1… % $ 2… $ 2… 6.7 %
…
… 2… (…
… 1… % 8… % b… 9… % 1… % b…
…
… 1… —
… 1… % 1… % b… 1… % 1… % b…
…
(1) Consists of severance, facility closures, and other charges
associated with restructuring programs.
Consists of legal, consulting, and other transaction and integration
(2) fees, and adjustments to contingent consideration, as well as other
purchase accounting related charges and other costs directly related
to the transactions.
Costs and other adjustments related to the Spin-Off and separation
(3) from GE, including system implementations, audit and advisory fees,
legal entity separation, Founders Grant equity awards, separation
agreements with GE, and other one-time costs.
(4) Consists of gains and losses resulting from the sale of assets and
investments.
Primarily relates to valuation adjustments for equity investments and
(5) for the nine months ended September 30, 2025, includes the impact
from the revaluation of our existing 50% interest in NMP as part of
the acquisition transaction.
(6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs
incurred in the year ended December 31, 2025.
* Non-GAAP financial measure.
F… F…
A… t… t…
N… t… n…
I… m… m…
($ e… e…
in S… % S… %
m… U… 20… 30 20… ch… 20… 30 20… ch…
──────────────────────────────────────────────────────────────────────────────
N…
i…
a… $ 6… $ 4… 3… % $ 1… $ 1… 4… %
to
GE
H…
A…
N…
b… -… -… -… -…
(…
c…
A…
R… 17 31 92 71
c…
A…
A…
a… 11 9 57 24
d…
c…
(…
A…
S…
a…
s… 4 6 2 40
c…
a…
o…
a…
A…
(…
l…
on -2 — -2 -5
b…
a…
a…
d…
A…
A…
of 61 41 1… 1…
a…
i…
a…
A…
I…
r… 6 -4 14 -…
(…
l…
L…
T… 9 — 1… —
r…
A…
T…
e… -7 -2 -… -3
of
r…
i…
A…
S…
a… -… 39 -… 22
o…
t…
a…
A…
n… $ 6… $ 4… 2… % $ 1… $ 1… 9… %
i…
(1) Consists of severance, facility closures, and other charges
associated with restructuring programs.
Consists of legal, consulting, and other transaction and integration
(2) fees, and adjustments to contingent consideration, as well as other
purchase accounting related charges and other costs directly related
to the transactions.
Costs and other adjustments related to the Spin-Off and separation
from GE, including system implementations, audit and advisory fees,
legal entity separation, Founders Grant equity awards, separation
(3) agreements with GE, and other one-time costs. For the nine months
ended September 30, 2025, an adjustment is included to eliminate the
associated impact on Net (income) loss attributable to noncontrolling
interests for applicable costs that impact earnings attributable to
noncontrolling interests.
(4) Consists of gains and losses resulting from the sale of assets and
investments.
Primarily relates to valuation adjustments for equity investments and
(5) for the nine months ended September 30, 2025, includes the impact
from the revaluation of our existing 50% interest in NMP as part of
the acquisition transaction.
Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs
incurred in the year ended December 31, 2025. The associated tax
(6) effect is presented on the Tax effect of reconciling items line. The
net of tax impact of tariff refunds is $7 million and $88 million for
the three and nine months ended September 30, 2026, respectively.
The tax effect of reconciling items is calculated using the statutory
(7) tax rate, taking into consideration the nature of the items and the
relevant taxing jurisdiction.
Consists of certain income tax adjustments, including foreign income
tax reserve releases and discrete tax impacts resulting from the
Spin-Off and separation from GE. Additionally, includes the impact of
(8) a foreign tax audit settlement for the three and nine months ended
September 30, 2026; impacts from tax law changes for the three and
nine months ended September 30, 2025; and tax impacts of the NMP
acquisition for the nine months ended September 30, 2025.
* Non-GAAP financial measure.
A…
E…
P…
S…
(…
d… For For
e… the the
s… th… ni…
o… mo… mo…
p… en… en…
in Se… $ Se… $
m… Un… 20… 30 20… ch… 20… 30 20… c…
──────────────────────────────────────────────────────────────────────────────
D…
e… $ 1.… $ 0.… $ 0.… $ 3.… $ 3.… $ 0.…
p…
s…
A…
N…
b… -0… -0… -0… -0…
(…
c…
A…
R… 0.… 0.… 0.… 0.…
c…
A…
A…
a… 0.… 0.… 0.… 0.…
d…
c…
(…
A…
S…
a…
s… 0.… 0.… 0.… 0.…
c…
a…
o…
a…
A…
(…
l…
on -0… — -0… -0…
b…
a…
a…
d…
A…
A…
of 0.… 0.… 0.… 0.…
a…
i…
a…
A…
I…
r… 0.… -0… 0.… -0…
(…
l…
L…
T… 0.… — 0.… —
r…
A…
T…
e… -0… -0… -0… -0…
of
r…
i…
A…
S…
a… -0… 0.… -0… 0.…
o…
t…
a…
A…
e… $ 1.… $ 1.… $ 0.… $ 3.… $ 3.… $ 0.…
p…
s…
D…
w… 453 457 455 458
s…
o…
(1) Consists of severance, facility closures, and other charges
associated with restructuring programs.
Consists of legal, consulting, and other transaction and integration
(2) fees, and adjustments to contingent consideration, as well as other
purchase accounting related charges and other costs directly related
to the transactions.
Costs and other adjustments related to the Spin-Off and separation
from GE, including system implementations, audit and advisory fees,
legal entity separation, Founders Grant equity awards, separation
(3) agreements with GE, and other one-time costs. For the nine months
ended September 30, 2025, an adjustment is included to eliminate the
associated impact on Net (income) loss attributable to noncontrolling
interests for applicable costs that impact earnings attributable to
noncontrolling interests.
(4) Consists of gains and losses resulting from the sale of assets and
investments.
Primarily relates to valuation adjustments for equity investments and
(5) for the nine months ended September 30, 2025, includes the impact
from the revaluation of our existing 50% interest in NMP as part of
the acquisition transaction.
Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs
incurred in the year ended December 31, 2025. The associated tax
(6) effect is presented on the Tax effect of reconciling items line. The
net of tax impact of tariff refunds is $0.02 and $0.19 for the three
and nine months ended September 30, 2026, respectively.
The tax effect of reconciling items is calculated using the statutory
(7) tax rate, taking into consideration the nature of the items and the
relevant taxing jurisdiction.
Consists of certain income tax adjustments, including foreign income
tax reserve releases and discrete tax impacts resulting from the
Spin-Off and separation from GE. Additionally, includes the impact of
(8) a foreign tax audit settlement for the three and nine months ended
September 30, 2026; impacts from tax law changes for the three and
nine months ended September 30, 2025; and tax impacts of the NMP
acquisition for the nine months ended September 30, 2025.
* Non-GAAP financial measure.
Adjus…
Tax
Expen… For the For the
and three nine
Adjus… months months
ETR* ended ended
Unaud… Septem… Septem…
($ in 30 30
milli… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Benef…
(prov…
for $ -129 $ -179 $ -342 $ -395
income
taxes
Add:
Tax
effect -7 -2 -16 -3
of
recon…
items…
Add:
Spin-…
and -37 39 -45 22
other
tax
adjus…
Adjus…
tax $ -174 $ -142 $ -402 $ -377
expen…
Effec…
tax 17.1% 27.8% 17.5% 20.3%
rate
Adjus…
effec… 22.0% 21.8% 19.9% 20.2%
tax
rate*
The tax effect of reconciling items is calculated using the statutory
(1) tax rate, taking into consideration the nature of the items and the
relevant taxing jurisdiction.
Consists of certain income tax adjustments, including foreign income
tax reserve releases and discrete tax impacts resulting from the
Spin-Off and separation from GE. Additionally, includes the impact of
(2) a foreign tax audit settlement for the three and nine months ended
September 30, 2026; impacts from tax law changes for the three and
nine months ended September 30, 2025; and tax impacts of the NMP
acquisition for the nine months ended September 30, 2025.
For For
F… the the
C… th… ni…
F… mo… mo…
U… en… en…
($ Se… Se…
in 30 % 30 %
m… 20… 20… ch… 20… 2… c…
──────────────────────────────────────────────────────────────────────────────
C…
f…
(… $ 907 $ 593 52… $ 1,… $ 937 45…
f…
o…
a…
A…
A…
to
P… -1… -1… -3… -3…
a…
i…
s…
A…
D… — — — —
of
P…
F…
c… $ 793 $ 483 64… $ 973 $ 589 65…
f…
Non-GAAP financial measures in outlook
GE HealthCare calculates forward-looking non-GAAP financial measures, including
Organic revenue growth, Adjusted EBIT margin, Adjusted ETR, Adjusted EPS, and
Free cash flow based on internal forecasts that omit certain amounts that would
be included in U.S. GAAP financial measures. GE HealthCare does not provide
reconciliations of these forward-looking non-GAAP financial measures to the
respective U.S. GAAP metrics as it is unable to predict with reasonable
certainty and without unreasonable effort certain items such as the impact of
changes in currency exchange rates, impacts associated with business
acquisitions or dispositions, timing and magnitude of restructuring activities,
and revaluation of strategic investments, amongst other items. The timing and
amounts of these items are uncertain and could have a substantial impact on GE
HealthCare’s results in accordance with U.S. GAAP.
Key performance indicators
Management uses the following metrics to provide a leading indicator of current
business demand from customers for products and services.
• Organic orders growth: Rate of change period-over-period of contractual
commitments with customers to provide specified goods or services for an agreed
upon price, and excluding the effects of: (1) recent acquisitions and
dispositions with less than a full year of comparable orders; and (2) foreign
currency exchange rate fluctuations in order to present orders on a constant
currency basis.
• Book-to-bill: Total orders divided by Total revenues within a given financial
period (e.g., quarter or FY).
* Non-GAAP financial measure.
Conference call and webcast information
GE HealthCare will discuss its results during its live earnings c all tod ay,
October 28, 2026 at 8:30 am ET/7:30 am CT. The webcast and accompanying slide
presentation containing financial information can be accessed by visiting the
investor section of the website at https://investor.gehealthcare.com/news-
events/events. An archived version of the webcast will be available on the
website after the call.
Forward-looking statements
This release contains forward-looking statements. These forward-looking
statements might be identified by words, and variations of words, such as
“will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,”
“intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,”
“outlook,” and similar expressions. These forward-looking statements may
include, but are not limited to, statements about the Company’s business and
expected financial performance, financial condition, and results of operations,
including revenue, revenue growth, profit, taxes, earnings per share, and cash
flows, and the Company’s outlook; changes in the Company’s leadership and
related impacts; and the Company’s strategy, innovation, and acquisitions and
investments. These forward-looking statements involve risks and uncertainties,
many of which are beyond the Company’s control. Factors that could cause the
Company’s actual results to differ materially from those described in its
forward-looking statements include, but are not limited to, operating in highly
competitive markets; global geopolitical and economic instability, including as
a result of changes in trade and tariff policy, and international conflicts and
tensions, including between Ukraine and Russia, in the Middle East, and in other
regions; public health crises, epidemics, and pandemics, and their effects on
the Company’s business; changes in or elimination of government subsidies, and
changes in third-party and government reimbursement processes, rates, and
contractual relationships, including related to government shutdowns, and
changes in the mix of public and private payers; demand for the Company’s
products, services, or solutions and factors that affect that demand;
developments in the market in China; the Company’s ability to control increases
in healthcare costs and any subsequent effect on demand for the Company’s
products, services, or solutions; the Company’s ability to successfully complete
strategic transactions; the actions or inactions of third parties with whom the
Company partners and the various collaboration, licensing, and other
partnerships and alliances the Company has with third parties; the impacts
related to the Company’s increasing focus on and investment in cloud, edge
computing, artificial intelligence, and software offerings; management of the
Company’s supply chain and the Company’s ability to cost-effectively secure the
materials it needs to operate its business; disruptions in the Company’s
operations; the impact of potential information technology, cybersecurity, or
data security breaches; maintenance and protection of the Company’s intellectual
property rights, as well as maintenance of successful research and development
efforts with respect to commercially successful products and technologies; the
Company’s ability to attract and/or retain key talent and qualified employees;
increasing attention to sustainability matters; compliance with the various
legal, regulatory, tax, privacy, and other laws to which the Company is subject,
such as the Foreign Corrupt Practices Act and similar anti-corruption and anti-
bribery laws globally, and related changes, claims, inquiries, investigations,
or actions; the impact of potential product liability claims or potential
litigation, arbitration, or similar proceedings; the Company’s level of
indebtedness and the impact of complying with the covenants and other terms of
the Company’s debt instruments on its business. Please also see Item 1A, “Risk
Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2025, filed with the U.S. Securities and Exchange Commission and
any updates or amendments it makes in future filings. There may be other factors
not presently known to the Company or which it currently considers to be
immaterial that could cause the Company’s actual results to differ materially
from those projected in any forward-looking statements the Company makes. The
Company does not undertake any obligation to update or revise its forward-
looking statements except as required by applicable law or regulation.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced
medical technology, pharmaceutical diagnostics, and AI, cloud and software
solutions that help clinicians tackle the world’s most complex diseases. Serving
patients and providers for 130 years, GE HealthCare is delivering bold
innovations designed for the next era of medicine across its Advanced Imaging
Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments to
help clinicians deliver more personalized, precise patient care. We are a $20.6
billion business with approximately 54,000 colleagues working to create a world
where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest
news and perspectives.
Investor Relations Contact:
Carolynne Borders
+1-631-662-4317
carolynne.borders@gehealthcare.com
Media Contact:
Jennifer Fox
+1-414-530-3027
jennifer.r.fox@gehealthcare.com